IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock? [Yahoo! Finance]
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Yahoo! Finance
to softer sales of its sole marketed product, Linzess (linaclotide), during the fourth quarter of 2025. The stock has plunged 14.2% over the past month, while the industry has decreased 6.2%. IRWD shares have also underperformed the sector and the S&P 500 in this timeframe, as seen in the chart below. Zacks Investment Research Image Source: Zacks Investment Research Linzess is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven years and above. The drug is also approved for treating functional constipation in children and adolescents aged six to 17 years. Despite gaining momentum in recent times, Linzess sales were soft during the fourth quarter of 2025, resulting in a reduced share of net profit for Ironwood. Per management, the decline in Linzess sales was largely due to gross-to-net rebate adjustments and higher pricing pressure from the Medicare Part D redesign, and not underlying demand. Let's anal
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- Astellas Pharma (ALPMY) was upgraded by Jefferies Financial Group Inc. from "hold" to "strong-buy".MarketBeat
- IsomAb appoints Dr Philip Brainin as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- JAMP Pharma Group Expands Oncology Portfolio with PrJAMP Enzalutamide [Yahoo! Finance]Yahoo! Finance
- BioNTech's Founding Duo Will Leave to Start New mRNA Firm [Yahoo! Finance Canada]Yahoo! Finance Canada
- BioNTech's Founding Duo Will Leave to Start New mRNA Firm [Yahoo! Finance]Yahoo! Finance